Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

C de la Piedra *,1, A Alcaraz2, J Bellmunt3, C Meseguer4, A Gómez-Caamaño5, M J Ribal6, F Vázquez7, U Anido9, P Samper9, E Esteban10, J L Álvarez-Ossorio11, P C Lara12, L A San José13, J A Contreras14, A G del Alba15, B González-Gragera16, A J Taberner17, C González-Enguita18, J M Fernández19, A García-Escudero20, F Gómez-Veiga21, M J Méndez22, J Segarra23, J A Virizuela24, J Carles25, A Lassa26, V Calderero27, M Constela28, D Delgado29, A Mañas30, A Murias31, G Reyes32, B Rodríguez33, G Rubio34, E Sánchez35, M Unda36, E Solsona37, J M Martínez-Javaloyas38, J Comet-Batle39, C Quíjano18, M Martín-Fernández1, I Mahillo-Fernández40 and J Morote41

1Bioquímica Investigación, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain; 2Servicio de Urología, Hospital Clínic i Provincial, Barcelona, Spain; 3Servicio de Oncología, Hospital del Mar, Barcelona, Spain; 4Departamento Médico, Novartis Farmacéutica, Barcelona, Spain; 5Servicio de Radioterapia, Complejo Hospitalario Universitario, Santiago de Compostela, Spain; 6Servicio de Urología, Hospital Clínic i Provincial, Barcelona, Spain; 7Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain; 8Servicio de Oncología, Complejo Hospitalario Universitario, Santiago de Compostela, Spain; 9Servicio de Radioterapia, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain; 10Servicio de Oncología, Hospital Universitario Central de Asturias, Oviedo, Spain; 11Servicio de Oncología, Hospital Universitario Puerta del Mar, Càdiz, Spain; 12Servicio de Oncología Radioterápica, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain; 13Servicio de Urología, Hospital Clínic San Carlos, Madrid, Spain; 14Servicio de Oncología, Hospital Universitario Puerta del Mar, Càdiz, Spain; 15Servicio de Oncología, Hospital Universitario Son Espases, Palma de Mallorca, Spain; 16Servicio de Oncología, Hospital Son Llatzer, Palma de Mallorca, Spain; 17Servicio de Urología, Hospital La Paz, Madrid, Spain; 18Servicio de Urología, Fundación Jiménez Díaz-Ute, Madrid, Spain; 19Servicio de Urología, Hospital Universitario Central de Asturias, Oviedo, Spain; 20Servicio de Urología, Hospital Txagorritxu, Vitoria, Spain; 21Servicio de Urología, Complejo Hospitalario Universitario Juan Canalejo, La Coruña, Spain; 22Servicio de Oncología, Hospital Reina Sofía, Córdoba, Spain; 23Servicio de Urología, Hospital Universitario Joan XXIII, Tarragona, Spain; 24Servicio de Oncología, Hospital Virgen Macarena, Sevilla, Spain; 25Servicio de Oncología, Hospital Vall d’Hebron, Barcelona, Spain; 26Servicio de Urología, Hospital Miguel Servet, Zaragoza, Spain; 27Servicio de Oncología, Hospital Montecelo, Pontevedra, Spain; 28Servicio de Oncología, Hospital Universitario Nuestra Señora de Candelaria, Gran Canaria, Spain; 29Servicio de Radioterapia, Hospital La Paz, Madrid, Spain; 30Servicio de Oncología, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain; 31Servicio de Oncología, Hospital Universitario La Fe, Valencia, Spain

*Correspondence: Dr C de la Piedra; E-mail: cpiedra@fjd.es

Received 26 March 2013; revised 9 May 2013; accepted 13 May 2013; published online 30 May 2013

© 2013 Cancer Research UK. All rights reserved 0007 – 0920/13
Background: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk, disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA).

Methods: This was an observational, prospective and multicenter study in which ninety-eight patients were included. Patients were treated with ZA (4 mg every 4 weeks for 18 months). Data were collected at baseline and 3, 6, 9, 12, 15 and 18 months after the beginning of treatment. Serum levels of bone alkaline phosphatase (BALP), aminoterminal propeptide of procollagen type I (P1NP) and beta-isomer of carboxiterminal telopeptide of collagen I (β-CTX) were analysed at all points in the study. Data on disease progression, SREs development and survival were recorded.

Results: Cox regression models with clinical data and bone markers showed that the levels of the three markers studied were predictive of survival time, with β-CTX being especially powerful, in which a lack of normalisation in visit 1 (3 months after the beginning of treatment) showed a 6.3-times more risk for death than in normalised patients. Levels of these markers were also predictive for SREs, although in this case BALP and P1NP proved to be better predictors. We did not find any relationship between bone markers and disease progression.

Conclusion: In patients with PCa and bone metastases treated with ZA, β-CTX and P1NP can be considered suitable predictors for mortality risk, while BALP and P1NP are appropriate for SREs. The levels of these biomarkers 3 months after the beginning of treatment are especially important.

Metastases are the most deadly events in the progression of cancer and are commonly associated with poor prognosis. The skeleton is one of the most common organs to be affected by metastatic cancers. One such cancer is prostate cancer (PCa). Patients with bone metastases have a high degree of morbidity and present with severe pain and high incidence of hypercalcemia, spinal cord compression and pathological fractures. These skeletal-related events (SREs) lead to a reduction in the quality of life and survival rate and constitute an important public-health problem (Coleman, 1997; Mundy, 2002).

Depending on the primary tumour, bone metastases can be either lytic or blastic with respect to bone. Tumoral cells release factors that activate osteoclasts or osteoblasts. PCa bone metastases are blastic in nature. Our body compensates for the increase of bone resorption, by increasing bone formation or resorption, respectively, by means of the coupling phenomenon. Owing to this fact, patients with bone metastases present a higher degree of bone remodelling than healthy individuals, thereby making bone remodelling a useful indicator when diagnosing bone metastases.

Biochemical markers of bone turnover (formation or resorption) are substances present in serum or urine that allow us to measure the activity of osteoblasts and osteoclasts. These characteristics could make these markers useful tools in quantifying the degree of alteration of bone remodelling in the presence of bone metastases. Bisphosphonates, compounds that directly produce osteoclastic inhibition, have been used in the treatment of patients with bone metastases because they reduce the increase in osteoclastic activity produced by the presence of such metastases. Bisphosphonates are useful in the case of blastic or lytic metastases, due to the coupling phenomenon. The decrease in bone resorption and the concomitant decrease in bone formation lead to a decrease in the release of factors that also decrease metastatic growth (Buijs and Pluijim, 2009; Coleman et al, 2010).

All commercial bisphosphonates have been used to treat bone metastases, but zoledronic acid (ZA) is currently the preferred option due to its great potency and its ability to be administered less frequently (Polascik and Mouraviev, 2008). Zoledronic acid administration produces a significant decrease in bone remodelling in patients with bone metastases.

Bone scintigraphy is commonly used to assess the extent of bone metastases; its use is limited in monitoring of treatment efficacy because it is an expensive, time-consuming technique. Moreover, scintigraphy presents sensitivity but lacks specificity, primarily due to slow detectable changes, and the confounding appearance of lesions containing mixed and/or osteosclerotic areas (Cook and Fogelman, 2000). For this reason, it would be of great interest to have biochemical markers that could accurately predict bone metastases and allow for effective follow-up of the progress of disease. Biochemical markers of bone turnover may meet this need.

Previous studies suggest that the levels of bone markers are correlated with the presence, extent and progression of bone metastases, including SREs, disease progression and death (Leeming et al, 2006; Lipton et al, 2007; Lein et al, 2007). However, more studies are necessary in order to obtain more definitive conclusions.

The aim of this work was to study the levels of two biochemical markers of bone formation, bone alkaline phosphatase (BALP) and aminoterminal propeptide of procollagen I (P1NP), and one marker of bone resorption, beta-isomer of carboxiterminal telopeptide of collagen I (β-CTX), in a population of patients with PCa and bone metastases. Markers were studied in basal conditions and 3, 6, 9, 12, 15 and 18 months after the beginning of treatment with ZA, and their relationship with mortality, disease progression and SREs was analysed. Prostatic-specific antigen (PSA) levels and their correlation with bone markers were also analysed.
Bone turnover markers in prostate cancer with bone metastases

**MATERIALS AND METHODS**

**Study group.** The TUGAMO (‘Tumores Urogenitales Avanzados, Metástasis Oseas’, advanced urogenital tumours, bone metastases) was an observational, prospective and national multicenter study (n = 40 centres) performed in patients with prostate, renal cells and bladder cancer with bone metastases. This manuscript studies a subgroup of these patients with PCa. Male patients ≥18 years old with histologically confirmed PCa with at least one diagnosed bone-lesion confirmed by bone scintigraphy were enrolled. Patients were excluded from the study if they presented with concomitant pathologies that could interfere in the evaluation of biochemical markers of bone turnover such as bone metabolic disorders, Paget’s disease of bone, hyperparathyroidism, thyroid abnormalities, abnormal intestinal absorption or hepatic or renal alterations. Patients treated with bisphosphonates prior to their inclusion in the study and with dental infection and diagnosis of mandibular osteonecrosis were also excluded.

Ninety-eight patients with PCa and bone metastases were included in the study. Sixty had previously received hormonal treatment and 38 had received no prior treatment. Once ZA treatment was established, none of the patient received hormonal treatment. Table 1 shows the demographics and baseline disease characteristics of the patients studied.

A follow-up of the patients was performed over 18 months. Baseline values (visit 0, v₀) were those obtained when a patient initiated treatment with ZA (Zometa, Novartis Pharma, Basel, Switzerland), 4 mg every 4 weeks over 18 months. During the study, administration of medication and standard antineoplasic therapies, including cytotoxic chemotherapy agents were also allowed. Data were collected at v₁, v₂ (3 months), v₃ (6 months), v₄ (9 months), v₅ (12 months), v₆ (15 months) and v₇ (18 months). The definition of SREs included pathological fractures, severe pain, hypercalcemia and spinal cord compression. Patients were also evaluated for disease progression by physical examination, including evaluation of ECOG performance and ECOG pain score.

**Table 1. Patients demographics and baseline disease characteristics**

| Variable                      | Value   |
|-------------------------------|---------|
| Mean age (years)              | 71.9 ± 8.4 |
| Weight (kg)                   | 77.5 ± 15.1 |
| Primary therapy n (%)         |         |
| Hormonal therapy              | 60 (63%) |
| None                          | 35 (37%) |
| Prior skeletal-related events n (%) |         |
| Yes                           | 2       |
| No                            | 93      |

| Soloway classification n (%)  |         |
| <6 Bone metastases           | 42 (44.2%) |
| 6–20 Bone metastases         | 30 (31.6%) |
| > 20 Bone metastases         | 11 (11.6%) |
| Super scan                   | 12 (12.1%) |

| Time from bone metastases diagnosis (months) | 1.8 ± 2.1 |
| BALP (µg l⁻¹)                              | 125 ± 215 |
| P1NP (ng ml⁻¹)                             | 393 ± 766 |
| β-CTX (ng/ml⁻¹)                            | 0.93 ± 1.113 |

Ninety-eight patients with PCa and bone metastases.

This study was approved by the Ethics Committee of the Unitat d’Evaluació, Suport I Prevenció of Clinical Hospital of Barcelona (Spain). Informed consent was obtained from each patient before the study began.

**Markers evaluation.** Bone alkaline phosphatase was determined by ELISA (IDS, Boldon, UK). Inter- and intra-assay coefficients of variation of the method were <6.4% and <4.5%. Sensitivity was 0.7 µg l⁻¹. The normal range for healthy adult men was ≤15 µg/L. PINP was determined by electrochemiluminescence (Elecys, Roche, Mannheim, Germany). Inter- and intra-assay coefficients of variation of the method were 3.7% and 2.9%. Sensitivity was 5 ng ml⁻¹. The normal range for healthy adult men was ≤62 ng ml⁻¹. Beta-isomer of carboxitfermin telopeptide of collagen I was determined by electrochemiluminescence (Elecys, Roche). Inter- and intra-assay coefficients of variation of the method were 4.7% and 4.6%. Sensitivity was 0.070 ng ml⁻¹. The normal range for healthy adult men was ≤4 ng ml⁻¹.

**Statistical analyses.** Bone markers were summarised in terms of mean, s.d., median and quartiles. Absolute and relative changes in bone markers as compared with baseline and previous visit were assessed at each visit. Absolute changes were summarised by mean and s.d. and their statistical significance was assessed by Wilcoxon test for paired samples. Relative changes were converted to logarithms and summarised by geometric mean and s.d. Their statistical significance was assessed using the Student’s t-test for paired samples.

Receiver operating characteristic (ROC) analysis were performed to evaluate the predictive capability of bone markers levels for mortality, SREs and progression, obtaining the cutoff point that maximises sensitivity and specificity. Receiver operating characteristic curves were performed (1) with the baseline bone markers levels and (2) with changes in bone markers in v₁ with respect to v₀ (defined as marker in v₁/marker in v₀). Then, survival curves were constructed using the Kaplan–Meier method by taking into account four classifications, and comparisons were performed using the log-rank test:

1. Biomarker ‘higher than’ or ‘equal to or lesser than’ the upper limit of normality.
2. Basal biomarker ‘higher’ or ‘equal to or lesser than’ than the ‘cutoff’ obtained from the ROC curves of basal values against death, SREs appearance or disease progression.
3. Biomarker value in v₁/biomarker in v₀ ‘higher’ or ‘equal to or lesser than’ the ‘cutoff’ obtained from the corresponding ROC curves.
4. Normal or non-normal level of bone markers at v₁.

Finally, Cox regression models were fitted to quantify the degree of association between potential predictors and mortality, the occurrence of SREs and progression. The models were summarised by hazard ratio estimate, s.e. and 95% confidence interval (CI) for hazard ratio. Also the P-value from hypothesis testing of the hazard ratio was shown.

We estimated the size of the hazard ratios in order that the study could present a statistical power of 80%. For this purpose, hazard ratios magnitudes, accumulated incidence of the study event (death, progression or SREs) and size of the compared groups were considered. According to these considerations, the hazard ratios that could detect results with a potency of 80% were >2.7 for death, >1.9 for progression and >2.5 for EREs appearance. The significance level was set at 0.05 for all tests.
RESULTS

Bone markers and PSA levels at baseline and after treatment with ZA. The concentrations of bone markers did not differ significantly between the groups of patients with hormonal therapy and without previous hormonal treatment both in basal conditions and after treatment with ZA. Thus, all subsequent calculations were performed with the data obtained from all patients in the respective groups.

At baseline, patients with PCa and bone metastases exhibited elevated levels of bone markers, and a significant correlation was found between values obtained from markers and Soloway classification (Soloway et al., 1998), (Tables 1 and 2).

Table 3 shows the percentages of patients with pathological levels of bone markers throughout the study. Zoledronic acid treatment produced a gradual increase of the percentage of patients with normal levels of biomarkers. Beta-isomer of carboxiterminal telopeptide of collagen I is the marker that experienced the highest degree of normalisation, with 93.3% of patients exhibiting normal levels after 18 months of ZA treatment.

Table 4 shows the mean values of biochemical markers of bone turnover throughout the study. Levels of markers tended to decrease significantly until vs 2 visit. From this point, no significant change was observed. As expected, levels of PSA in patients with previous hormonal treatment were lower than in those without previous treatment (mean value: 5.9 ng ml$^{-1}$, 95% Cl: 3.0–11.6 vs 64.4 ng ml$^{-1}$, 95% Cl: 29.7–139.9, $P < 0.01$). After ZA treatment, values of PSA of previously untreated patients decreased significantly to the levels of treated patients (mean value: 7.80 ng ml$^{-1}$ vs 2.03 ng ml$^{-1}$), without significant differences between the two groups ($P < 0.09$) and without significant differences along the whole period of the study ($P < 0.47$). Levels of bone markers correlated positively with PSA values at baseline ($P < 0.001$ for the three studied markers) and at visits 1, 2, 3, 4 and 5 ($P < 0.001$ for BALP, $P < 0.01$ for P1NP and $P < 0.05$ for $\beta$-CTX). However, at visits 6 and 7, only values of BALP correlated with PSA levels ($P < 0.01$).

Global survival, defined as time between the beginning of treatment and death during the 18 months of treatment showed a mean value of 16.3 months. Ninety-eight patients started the study and 57 completed it. Losses of participants were due to death (21), failure to provide informed consent (4), loss to follow-up (7), clinical criteria (5) and others (change of address, renal insufficiency, etc. (4)).

Capability of bone biomarkers to predict mortality. With respect to mortality, using the first categorisation explained in Materials and Methods (biomarker ‘higher than’ or ‘equal to or lesser than’ the upper limit of normality), no significant differences were obtained in the Kaplan–Meier curves plotting survival time (data not shown). However, Kaplan–Meier analysis distinctly demonstrated different survival curves for the three bone markers studied, according to the second (biomarker ‘higher’ or ‘equal to or lesser than’ the ‘cutoff’ obtained from the ROC curves of basal values against death) (Figure 1), the third (biomarker value in $v_0$/biomarker in $v_0$ ‘higher’ or ‘equal to or lesser than’ the cutoff obtained from the corresponding ROC curves) (Figure 2A) and the fourth (normal or non-normal level of bone markers at $v_1$) classifications (Figure 2B). Tables 5 and 6 show the univariate Cox regression analysis derived from the above mentioned Kaplan–Meier curves. The hazard ratio indicates how many times greater the risk of death was in the given group relative to the other group. The three markers studied could be useful as predictors of survival, although $\beta$-CTX levels in $v_1$ were especially significant in this regard. Our results show that values of $\beta$-CTX were especially relevant for survival during the 18 months of ZA treatment. A value of $v_1/v_0 > 0.4$ (a decrease of $\beta$-CTX in $v_1$ of <40%) and/or lack of normality in levels of $\beta$-CTX, indicates a six-fold increase in risk of mortality along the study. Similar behaviour, although with minor statistical potency presents P1NP values. A decrease of P1NP in $v_1$ of <15% and/or lack of normality, indicates a five-fold increase in the risk of mortality, and no changes in levels of BALP between $v_0$ and $v_1$ indicates an increase of three-fold in the risk of mortality.

Table 3. Percentages of patients with pathological levels of biochemical markers of bone turnover along the study

| Visit | $V_0$ | $V_1$ | $V_2$ | $V_3$ | $V_4$ | $V_5$ | $V_6$ |
|-------|-------|-------|-------|-------|-------|-------|-------|
| Numbers of patients | 98 | 95 | 87 | 77 | 66 | 58 | 57 |
| Marker BALP: elevated | 74.7 | 58.6 | 54.4 | 40.9 | 50.0 | 40.0 | 43.3 |
| Marker P1NP: elevated | 58.9 | 39.4 | 31.6 | 15.9 | 17.1 | 18.4 | 20.0 |
| Marker $\beta$-CTX: elevated | 47.9 | 31.0 | 17.5 | 11.4 | 10.0 | 7.9 | 6.7 |

Abbreviations: $\beta$-CTX = $\beta$-isomer of carboxiterminal telopeptide of collagen I; BALP = bone alkaline phosphatase; P1NP = amino-terminal propeptide of procollagen I.

Table 4. Levels of biochemical markers of bone turnover throughout the study

| Visit | Numbers of patients | BAP (\text{ng ml}^{-1}) | P1NP (\text{ng ml}^{-1}) | $\beta$-CTX (\text{ng ml}^{-1}) |
|-------|---------------------|--------------------------|--------------------------|--------------------------|
| $V_0$ | 98                  | 126.7 ± 208.8            | 399 ± 741                | 0.967 ± 1.094*          |
| $V_1$ | 95                  | 52.7 ± 74.4*             | 157 ± 253*               | 0.456 ± 0.612*          |
| $V_2$ | 87                  | 35.3 ± 62.9*             | 110 ± 224*               | 0.308 ± 0.384*          |
| $V_3$ | 77                  | 38.6 ± 80.0              | 71 ± 139*                | 0.255 ± 0.354*          |
| $V_4$ | 66                  | 35.3 ± 57.5*             | 52 ± 77.0                | 0.209 ± 0.255*          |
| $V_5$ | 58                  | 31.2 ± 49.6*             | 55 ± 146*                | 0.216 ± 0.267*          |
| $V_6$ | 57                  | 26.0 ± 33.9*             | 47 ± 174*                | 0.235 ± 0.252*          |

Abbreviations: $\beta$-CTX = $\beta$-isomer of carboxiterminal telopeptide of collagen I; BAP = bone alkaline phosphatase; P1NP = amino-terminal propeptide of procollagen I.

Patients with PCa and bone metastases.

Kruskal–Wallis.
Bone markers and disease progression. Distinctly than in the case of mortality, we did not find any association between bone marker levels and disease progression. Basal levels of bone biomarkers did not show any correlation with disease progression through Kaplan–Meier curves analysis. Normalisation of bone marker levels after ZA treatment or \( \frac{v_1}{v_0} \) marker levels ratio also failed to show any statistically significant association with disease progression. As we did not find any significant differences in Kaplan–Meier curves, Cox regression analysis was not performed.

Capability of bone biomarkers to predict SREs appearance. In the present work, two patients presented with SREs before the beginning of the study. Seven, 7, 5, 3, 2 and 2 new SREs were observed in \( v_1, v_2, v_3, v_4, v_5 \) and \( v_6 \) respectively. With respect to
Values of the three markers were closely related to the SREs, and Tables 7 and 8 show the univariate Cox regression analysis of SREs appearance. Figures 3A and B show the relevant results.

Table 5. Univariate Cox regression analysis of bone markers for survival prediction after 18 months of ZA treatment

| Marker | Hazard ratio | s.d.     | 95% CI        | P-value |
|--------|--------------|----------|---------------|---------|
| BALP   |              |          |               |         |
| V₀ elevated<sup>a</sup> | 1.469 | 0.9423 | 0.418–5.164 | 0.5485 |
| V₀ > 1.64<sup>b</sup> | 3.157 | 1.7406 | 1.071–9.302 | 0.0371 |
| V₁/V₀ > 1.00<sup>c</sup> | 3.048 | 2.2604 | 0.713–13.039 | 0.1328 |
| P1NP   |              |          |               |         |
| V₀ elevated<sup>d</sup> | 1.564 | 0.7847 | 0.585–4.181 | 0.3722 |
| V₀ > 1.48<sup>b</sup> | 3.372 | 1.6162 | 1.318–8.627 | 0.0112 |
| V₁/V₀ > 0.44<sup>c</sup> | 4.969 | 3.4755 | 1.261–19.573 | 0.0219 |
| β-CTX  |              |          |               |         |
| V₀ elevated<sup>d</sup> | 2.318 | 1.1262 | 0.894–6.007 | 0.0837 |
| V₀ > 1.1<sup>b</sup> | 2.954 | 1.4138 | 1.156–7.547 | 0.0237 |
| V₁/V₀ > 0.4<sup>c</sup> | 6.100 | 4.8328 | 1.291–28.820 | 0.0024 |

Abbreviations: β-CTX = β-isomer of carboxyterminal telopeptide of collagen I; BALP = bone alkaline phosphatase; P1NP = aminoterminal propeptide of procollagen I. Ninety-eight patients with PCa and bone metastases treated with zoledronic acid (4 mg every 4 weeks) during 18 months. V₀: basal visit; V₁: visit after 3 months following the beginning of the treatment.

<sup>a</sup>Biomarker ‘higher than’ the upper limit of normality.
<sup>b</sup>Biomarker ‘higher than’ the cut-off obtained from the ROC curves of basal values against death.
<sup>c</sup>Biomarker value in v₁/biomarker in v₀ ‘higher than the cut-off obtained from the corresponding ROC curves.

Table 6. Univariate Cox regression analysis of bone markers for survival prediction according to normalisation in V₁

| Marker | Hazard ratio | s.d.     | 95% CI        | P-value |
|--------|--------------|----------|---------------|---------|
| BALP   |              |          |               |         |
| No normalisation<sup>a</sup> | 2.029 | 1.4867 | 0.483–8.530 | 0.3341 |
| P1NP   |              |          |               |         |
| No normalisation<sup>a</sup> | 5.053 | 3.3285 | 1.389–18.376 | 0.0139 |
| β-CTX  |              |          |               |         |
| No normalisation<sup>a</sup> | 6.271 | 4.0944 | 1.744–22.548 | 0.0049 |

Abbreviations: β-CTX = β-isomer of carboxyterminal telopeptide of collagen I; BALP = bone alkaline phosphatase; P1NP = aminoterminal propeptide of procollagen I. Ninety-eight patients with PCa and bone metastases treated with zoledronic acid (4 mg every 4 weeks) during 18 months. V₁: visit after 3 months following the beginning of the treatment.

<sup>a</sup>Value of biomarker in V₁ higher than the upper limit of normality.

Discrimination of patients with PCa and bone metastases treated with zoledronic acid (4 mg every 4 weeks) during 18 months. V₀: basal visit; V₁: visit after 3 months following the beginning of the treatment.

It is important to point that all the values of hazard ratios that presented a statistical significance in the study, presented values higher than those considered to have a minimum of 80% of statistical power (see Materials and Methods).

Discussion

As higher levels of PSA are found with more advanced stages of PCa and with worse outcomes, PSA has been historically used as a staging and prognostic tool (Shariat et al, 2004). However, PSA is now commonly regarded as an indicator of prostate volume and is not independently diagnostic or prognostic in PCa. Owing to these limitations, there is an urgent need for new prognostic biomarkers to enhance the clinical management of PCa. This could be denominated the post-PSA era (Bickers et al, 2009).

To perform this work, we selected two biochemical markers of bone formation – BALP and P1NP – and one of bone resorption – β-CTX. Of these, BALP has high specificity, as it is a product only released by the active osteoblast and has demonstrated a great sensitivity for detecting increases in bone turnover (Garnero and Delmas, 1993). Its weakness, however, is that monoclonal antibodies against BALP exhibit a cross-reactivity of 15% with hepatic isoenzyme (Garnero and Delmas, 1993). As a result, values can be abnormally elevated in the presence of hepatic diseases. However, in our work, none of the PCa patients with bone metastases presented simultaneously with hepatic metastases. Thus, no interference of hepatic on bone isoenzyme was present. Aminoterminal propeptide of procollagen type I and β-CTX have been recently recommended by the International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine as reference markers in all clinical studies (Vaskaran et al, 2011).

In a first stage, biomarkers of bone formation and bone resorption were evaluated for their ability to act as useful tools for the diagnosis of bone metastases (Coleman, 1997; Leeming et al, 2006; Huang and Ouyang, 2012). All biomarkers were indicative of skeletal involvement, albeit with different sensitivity. In previous works, one group of authors of the present work found a sensitivity of 87.5% and a specificity of 100% for BALP (>30 ng ml⁻¹) in the detection of bone metastases in PCa (Lorente et al, 1996), the values of BALP being more efficient than PSA levels in the prediction of positive bone scans. De la Piedra et al (2003) found a specificity and sensitivity of 100% in the levels of P1NP and β-CTX. This high sensitivity and specificity was due to the fact that this is the only work in the literature in which all PCa patients were studied before any treatment was initiated. In the present work, the patients showed elevated baseline levels of BALP, P1NP and β-CTX. Brasso et al (2006) also found an elevation in these markers. The increase in the levels of bone formation at the onset of skeletal metastases reflects the dominant osteoblastic element of the bone remodelling process in these patients, although due to the coupling remodelling phenomena, markers of bone resorption are also elevated. This fact produces a high correlation between markers, as we found in the present work. The fact that bone metastases produce an increase in remodelling is corroborated by the correlation between bone markers levels and Soloway classification, as described in the present and previous works (Coleman, 1997; Leeming et al, 2006).

Although hormonal treatment tends to produce an increase in the levels of biochemical markers of bone turnover (Smith et al, 2004) (a tendency to higher values was observed in treated patients), in basal conditions, the concentration of bone markers did not differ significantly between patients with and without hormonal treatment. After ZA treatment, values of all markers decreased and values of bone markers of treated and untreated groups of patients were quite similar. This is the reason for which we performed all the subsequent calculations with the data obtained from all patients in the study group.

Owing to the antosteoclastic action of ZA, the first effect produced in bone turnover markers in prostate cancer with bone metastases
Figure 3. (A) Kaplan–Meier analysis for the appearance of SREs after the completion of treatment with zoledronic acid according to the ratio of level of biomarker in v1/level of biomarker in v0, for BALP, P1NP and β-CTX. The stratification was performed using the cutoff points obtained from the ROC curves of changes in bone markers in v1 with respect to v0 against SREs appearance. The cutoff points obtained in the ROC curves were 0.873 for BALP, 0.778 for P1NP and 0.539 for β-CTX. (B) Kaplan–Meier analysis for the appearance of SREs after the completion of treatment (18 months) with ZA according to the dichotomous criterion of achievement or not a normal level of bone markers in the v1 for P1NP and β-CTX. *Values of biomarkers into the normal range are indicated in Materials and Methods. Kaplan–Meier curve of BALP is not presented because differences between groups according to these criteria were not statistically significant.

Table 7. Univariate Cox regressing analysis of bone markers for SRES prediction after completion of ZA treatment.

| Marker | Hazard ratio | s.d. | 95% CI | P-value |
|--------|--------------|------|--------|---------|
| BALP   |              |      |        |         |
| V0 elevateda | 0.796 | 0.369 | 0.324–1.955 | 0.6192 |
| V0 > 78.4b | 2.052 | 0.898 | 0.870–4.841 | 0.1008 |
| V0/V0 > 0.873c | 4.068 | 2.164 | 1.434–11.540 | 0.0083 |
| P1NP   |              |      |        |         |
| V0 elevateda | 1.469 | 0.641 | 0.622–3.469 | 0.3801 |
| V0 > 135.6b | 1.993 | 0.839 | 0.875–4.551 | 0.1016 |
| V0/V0 > 0.778c | 2.905 | 1.452 | 1.091–7.738 | 0.0329 |
| β-CTX  |              |      |        |         |
| V0 elevateda | 2.303 | 0.988 | 0.993–5.340 | 0.0519 |
| V0 > 0.584b | 2.006 | 0.846 | 0.877–4.588 | 0.0991 |
| V0/V0 > 0.539c | 3.435 | 1.725 | 1.263–9.339 | 0.0156 |

Abbreviations: β-CTX = β-isomer of carboxyterminal telopeptide of collagen I; BALP = bone alkaline phosphatase; P1NP = aminoterminal propeptide of procollagen I. Ninety-eight patients with PCa and bone metastases treated with zoledronic acid (4 mg every 4 weeks).

Table 8. Univariate Cox regression analysis of bone markers for SRES prediction according to normalisation of values of bone markers at V1.

| Marker | Hazard ratio | s.d. | 95% CI | P-value |
|--------|--------------|------|--------|---------|
| BALP   |              |      |        |         |
| No normalisationa | 0.972 | 0.5056 | 0.351–2.694 | 0.9571 |
| P1NP   |              |      |        |         |
| No normalisationa | 2.900 | 1.4720 | 1.073–7.843 | 0.0359 |
| β-CTX  |              |      |        |         |
| No normalisationa | 3.847 | 1.9443 | 1.428–10.359 | 0.0077 |

Abbreviations: β-CTX = β-isomer of carboxyterminal telopeptide of collagen I; BALP = bone alkaline phosphatase; P1NP = aminoterminal propeptide of procollagen I. Ninety-eight patients with PCa and bone metastases treated with zoledronic acid (4 mg every 4 weeks) during 18 months. V1: visit after 3 months following the beginning of the treatment. aValue of biomarker in V1 higher than the upper limit of normality.

β-CTX, presenting a 93.3% of the patients normal values of this marker after 18 months of treatment.

Our results show that values of β-CTX were especially relevant for the prediction of survival during the 18 months of ZA treatment. A decrease of β-CTX in v1 of <40% and/or lack of normality in levels of β-CTX, indicates a six-fold increase in the risk of mortality along the study. Similarly, a decrease of P1NP in v1 of <44% and/or lack of normality, indicates a five-fold increase in the risk of mortality, and no changes in levels of BALP during 18 months. V1: visit after 3 months following the beginning of the treatment. Our results show that values of β-CTX were especially relevant for the prediction of survival during the 18 months of ZA treatment. A decrease of β-CTX in v1 of <40% and/or lack of normality in levels of β-CTX, indicates a six-fold increase in the risk of mortality along the study. Similarly, a decrease of P1NP in v1 of <44% and/or lack of normality, indicates a five-fold increase in the risk of mortality, and no changes in levels of BALP during 18 months. V1: visit after 3 months following the beginning of the treatment.
In the present work, we did not find any association between bone markers and disease progression. This result is consistent with that of Mounthzios et al (2010), who found that none of the bone markers were able to predict clinical outcomes. Santini et al (2006) also found a very limited impact of bone markers were able to predict clinical outcomes. Santini et al (2006) being the most potent. In this case, a value of \( v_1/v_0 > 0.873 \) in BALP (a decrease of BALP in \( v_1 \) of <87%) indicates a four-fold increase in the risk of SREs. The specific osteoblastic – and in consequence osseous – nature of BALP and P1NP could be the reason behind the close association between high bone formation levels and SREs, as compared with \( \beta\text{-CTX} \). Lein et al (2009) found that in PCa patients treated with ZA, a decrease of P1NP below 25% was predictive for SREs development.

CONCLUSIONS

In conclusion, use of bone markers and especially of \( \beta\text{-CTX} \), in the follow-up of patients with PCa and bone metastases improved prediction of the disease development, complementing predictions based exclusively on clinical data. The decrease in \( \beta\text{-CTX} \) following the first administration of ZA is closely correlated with survival, while the decrease in BALP and P1NP is a strong predictor of the appearance of SREs. Use of these three biomarkers provides an interesting advantage, not only for clinicians regarding clinical decisions, but also for patients regarding their own decisions on treatment planning.

ACKNOWLEDGEMENTS

This study was supported by Novartis Oncology Spain. As this was a multicenter study, Adknoma Health Research (Barcelona, Spain) collected and ordered data throughout the study. We especially thank Margarida Garcia from Adknoma who followed carefully the development of the study. M. Martín-Fernández was a fellow of the Conchita Rábago Foundation.

CONFLICT OF INTEREST

Cristina Meseguer is an employee of Novartis Farmacéutica, Spain. The other authors declare no conflict of interest.

REFERENCES

Bickers B, Aukhim-Hasie C (2009) New molecular biomarkers for the prognosis and management of prostate cancer. The post PSA era. Anticancer Res 29: 3289–3298.

Brasso K, Christensen II, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66: 503–513.

Buigs JT, Pujim G (2009) Osteotropic cancers: from primary tumor to bone. Cancer Lett 273: 177–193.

Coleman RE (1997) Skeletal complications of malignancy. Cancer 80: 1588–1594.

Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufulsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Siva LJ (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36: 615–620.

Cook GR, Fogelman I (2000) Diagnosis and monitoring on bone metastases: scintigraphy. In Tumor bone diseases and osteoporosis in cancer patients, Body J (ed) pp 131–154. Marcel Dekker: New York.

De la Piedra C, Castro-Erracobarde NA, Traba ML, Mendoza-Davila C, Garcia Moreno C, Rodriguez de Acuna L, Rodriguez Molina J (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45–53.

Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metastatic bone disease. J Clin Endocrin Metab 77: 1046–1053.

Huang Q, OuYang X (2012) Biochemical-markers for the diagnosis of bone metastasis: A clinical review. Cancer Epidemiology 36: 94–98.

Jung K, Miller K, Wirth M, Albrech M, Lein M (2011) Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 59: 604–612.

Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Támkó LB (2006) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate or lung cancer. Cancer Epidemiol Biomarkers Prev 15: 32–38.

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K (2007) Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52: 1381–1387.

Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K (2009) Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 69: 624–632.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12: 1035–1043.

Lorente JA, Morote J, Raveontos C, Encabo G, Valenzuela H (1996) Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155: 1348–1351.

Mounthzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Barbatis A, Movrikakis M, Dimopoulos MA (2010) Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the bisphosphonates zoledronic acid. Transl Res 155: 247–255.

Mundy GR (2002) Metastases to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593.

Polascik TJ, Mounavie V (2008) Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 4: 261–268.

Santini D, Vicenzi B, Hannon RA, Brown JE, Dicouzino G, Angelesi S, La Cesa A, Coleman RE, Tonini G, Buddlon A, Caraglia M, Holen I (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15: 1351–1357.

Shariat SF, Canto EI, Kattan MW, Slawin KM (2004) Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6: 58–72.

Smith MR, Goode MJ, Zietman AL, McGovern PJ, Lee H, Finkelstein JS (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22: 2546–2553.

Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Solowsay S, Moiuddin M (1998) Stratification of patients with prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195–202.

Vaskaran S, Eastell R, Buryovre O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Treinti T, Wahl DA, Cooper C, Kanis JA. IOF-JFCC Bone Marker Standards Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 22: 391–420.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.